Edoc Acquisition Corp. (ADOC) to Combine with Calidi Biotherapeutics, Inc. in $449M Deal

Feb 2, 2022 INTEL by Marlena Haddad

Edoc (Nasdaq:ADOC) has entered into a definitive agreement to combine with biotechnology firm Calidi Biotherapeutics, Inc. at an enterprise value of $449 million. La Jolla, California-Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that delivers oncolytic viruses for targeted therapy against difficult-to-treat cancers. The combined company is expected to trade on the Nasdaq
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

Edoc Acquisition Corp. (ADOC) to Combine with Calidi Biotherapeutics, Inc. in $449M Deal

Edoc Acquisition Corp. (ADOC) to Combine with Calidi Biotherapeutics, Inc. in $449M Deal

ByMarlena Haddad